Evaluation of the Use of Granulocyte Colony-Stimulating Factors (G-CSFs) for Neutropenia Primary Prophylaxis in Solid Tumors at a Tertiary Care Hospital, Retrospective Study

@article{Af2017EvaluationOT,
  title={Evaluation of the Use of Granulocyte Colony-Stimulating Factors (G-CSFs) for Neutropenia Primary Prophylaxis in Solid Tumors at a Tertiary Care Hospital, Retrospective Study},
  author={Alshehri Af and A. Alnatsheh and M. Aseeri and T. Alfayea},
  journal={Journal of Pharmacovigilance},
  year={2017},
  volume={5},
  pages={1-5}
}
  • Alshehri Af, A. Alnatsheh, +1 author T. Alfayea
  • Published 2017
  • Medicine
  • Journal of Pharmacovigilance
  • Objective: First, to determine the appropriate prescribing of granulocyte colony-stimulating factors (G-CSFs) for febrile neutropenia (FN) as primary prophylaxis during the first cycle of chemotherapy in breast, lung, gastric, esophageal, nasopharyngeal or colorectal cancer patients. Second, to compare the incidence of FN between patients who received G-CSF appropriately and inappropriately. Methods: This was a retrospective cohort study conducted at the Princess Norah bint Abdulrahman Al… CONTINUE READING
    2 Citations
    Appropriateness of using granulocyte colony-stimulating factor (G-CSF) for primary prophylaxis of febrile neutropenia in solid tumors
    Prescribing Pattern of Granulocyte Colony-stimulating Factor at Tertiary Care Hospital in Riyadh: An Observational Study
    • Highly Influenced
    • PDF

    References

    SHOWING 1-10 OF 52 REFERENCES
    Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.
    • 562
    • PDF
    Granulocyte Colony-Stimulating Factor Use in a Large Iranian Hospital: Comparison with American Society of Clinical Oncology (ASCO) Clinical Practice Guideline
    • 6
    Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy
    • 33
    Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
    • 78
    • PDF
    Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy.
    • 30
    Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
    • P. Bunn, J. Crowley, +7 authors D. Gandara
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 1995
    • 160
    Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer.
    • P. Jenkins, S. Freeman
    • Medicine
    • Annals of oncology : official journal of the European Society for Medical Oncology
    • 2009
    • 56